Pancreatic cancer and thromboembolic disease

Khorana, Alok A.; Fine, Robert L.

doi:10.1016/s1470-2045(04)01606-7

Cited by 231 publications

(170 citation statements)

References 59 publications

Supporting

Mentioning

161

Contrasting

Unclassified

Order By: Relevance

“…VTE is a common complication of malignancy (1,3,4) with varying rates among different cancers (35)(36)(37)(38)(39)(40) and especially high rates in GI malignancies (39,41). The development of VTE in patients with active cancer has several clinical implications including increased mortality (1,2,42).…”

Section: Discussionmentioning

confidence: 99%

Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma

Connolly

Chen

Hyrien

et al. 2008

Thrombosis Research

105

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma

Connolly

Chen

Hyrien

et al. 2008

Thrombosis Research

105

View full text Add to dashboard Cite

show abstract

“…As compared with other tumor types, patients with pancreatic cancer have an increased risk for developing VTEs. 18,19 Therapy with thalidomide, pomalidomide and lenalidomide [16][17][18] has also been associated with the development of VTEs. Though this is a non-randomized, uncontrolled trial, the rate of observed VTEs in this trial is concerning and may limit development of these compounds in this patient population unless full-dose LMWH or warfarin is used prophylactically.…”

Section: Patientmentioning

confidence: 99%

Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial

Infante

Arkenau

Bendell

et al. 2013

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…Thrombocytosis occurs because of the fact that pancreatic cancer commonly causes a hypercoagulable state resulting in a predisposition to thromboembolic events [8]. A number of proinflammatory mediators (notably IL-1, IL-3, and IL-6) are known to stimulate megakaryocyte proliferation [11]; therefore, the association between a relative thrombocytosis and adverse overall survival in pancreatic cancer might be explained on the basis that the platelet count reflects an additional index of systemic inflammation elicited by the tumor.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Role of Platelet Lymphocyte Ratio(PLR) in Pancreatic Head Masses

Miglani¹,

Bhateja

Bhat

et al. 2012

Indian J Surg

View full text Add to dashboard Cite

Masses in and around pancreas constitute an important clinical entity in gastrointestinal surgical practice. Most common being adenocarcinoma of head of pancreas followed by inflammatory masses due to chronic pancreatitis. Accurate diagnosis is of central importance as therapeutic strategies range from observation to complete surgical removal including total pancreatectomy.Several tumor markers are available which could help in prognostication and diagnosis of carcinoma pancreas. Carbohydrate antigen 19-9(CA 19-9) is traditionally accepted best marker available. The role of new tumor marker platelet lymphocyte ratio (PLR) has been defined recently in prognostication of carcinoma pancreas. Role of PLR in diagnosing and its efficacy after combining it with CA 19-9 is not known. The aim of study was to assess the demographics of histologically proven neoplastic and inflammatory pancreatic head masses in our department. To assess the role of CA19-9 and platelet lymphocyte ratio(PLR) in determining nature of pancreatic head mass. Data consisted of histologically proven 45 patients .23 having head mass due to chronic pancreatitis and 22 because of neoplastic lesions. Demographics in terms of age, sex, previous pain episodes, presence of jaundice, history of alcohol intake were compared in both groups. Also tumor markers CA 19-9 and PLR individually and in combination were compared in both groups. Cancer pancreas significantly (p<0.001) occurred in older age group, was significantly associated with jaundice (p00.005) and weight loss (p<0.001). Accuracy in diagnosis of cancer pancreas was similar with CA 19-9 and PLR (68.89 %), where as combining CA 19-9 with PLR showed increased sensitivity(81.82 %) and accuracy(71.11 %) in diagnosing cancer pancreas. Other combinations showed no advantage. PLR is at least as good as CA 19-9 as diagnostic marker to differentiate between malignant and inflammatory head mass of pancreas.

show abstract

Pancreatic cancer and thromboembolic disease

Cited by 231 publications

References 59 publications

Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma

Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma

Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial

Diagnostic Role of Platelet Lymphocyte Ratio(PLR) in Pancreatic Head Masses

Contact Info

Product

Resources

About